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bowel cancer screening programmes, according to seven key characteristics, and (ii) to explore the policy
trade-offs resulting from inadequate funding. Setting United Kingdom and Australia. Methods A comparative
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jurisdiction on seven key programme characteristics: screening frequency, population coverage, quality of test,
programme model, quality of follow-up, quality of colonoscopy and quality of data collection. A list of optimal
features for each of the seven characteristics was compiled, based on the FOBT screening literature and our
detailed examination of each programme. Results Each country made different implementation choices or
trade-offs intended to conserve costs and/or manage limited and expensive resources. The overall outcome of
these trade-offs was probable lower programme effectiveness as a result of compromises such as reduced
screening frequency, restricted target age range, the use of less accurate tests, the deliberate setting of low
programme positivity rates or increased inconvenience to participants from re-testing. Conclusions
Insufficient funding has forced programme administrators to make trade-offs that may undermine the
potential net population benefits achieved in randomized controlled trials. Such policy compromise
contravenes the principle of evidence-based practice which is dependent on adequate funding being made
available.
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Abstract
Objectives—(i) To document the current state of the English, Scottish, Welsh, Northern Irish
and Australian bowel cancer screening programmes, according to seven key characteristics, and
(ii) To explore the policy trade-offs resulting from inadequate funding.
Setting—United Kingdom and Australia.
Methods—A comparative case study design using document and key informant interview
analysis. Data was collated for each national jurisdiction on seven key programme characteristics:
screening frequency, population coverage, quality of test, programme model, quality of follow-up,
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quality of colonoscopy and quality of data collection. A list of optimal features for each of the
seven characteristics was compiled, based on the FOBT screening literature and our detailed
examination of each programme.
Results—Each country made different implementation choices or trade-offs intended to conserve
costs and/or manage limited and expensive resources. The overall outcome of these trade-offs was
probable lower programme effectiveness as a result of compromises such as reduced screening
frequency, restricted target age range, the use of less accurate tests, the deliberate setting of low
programme positivity rates, or increased inconvenience to participants from retesting.
Conclusions—Insufficient funding has forced programme administrators to make trade-offs that
may undermine the potential net population benefits achieved in randomized controlled trials.
Such policy compromise contravenes the principle of evidence-based practice which is dependent
on adequate funding being made available.
INTRODUCTION
Bowel cancer, also known as colorectal cancer, is the second largest cause of cancer death in
men and women combined in all four UK countries1 and in Australia.2 The UK National
Screening Committee (NSC)3 and the Australian Health Technology Advisory Committee4
concluded that screening for bowel cancer using faecal occult blood tests (FOBTs) satisfied
the criteria for population screening programmes. The UK5 and Australian pilot
programmes6 reviewed the evidence for the benefits, harms and cost-effectiveness of bowel
cancer screening in their own jurisdictions. Subsequently England, Scotland, Wales,
Northern Ireland and Australia have implemented different versions of FOBT bowel cancer
screening programmes.
A 2008 review of bowel cancer screening initiatives across 17 countries found FOBTs were
the most commonly used screening modality.7 There are good reasons for governments to
allocate funding for FOBT screening programmes. If the 25% relative mortality reduction
demonstrated in the intention-to-treat data from the most recent meta-analysis8 was
achieved, almost 4,000 lives in the UK and over 1,000 lives in Australia could be saved each
year. Bowel cancer screening can also lead to lower incidence of bowel cancer in the
screened population, as the removal of pre-cancerous adenomas prevents the disease
occurring.9 Conversely, the number and severity of potential harms from bowel cancer
screening are relatively small, as serious adverse events are rare, and anxiety associated with
it is believed to be relatively short-term and minor.10
In order to achieve the same or greater magnitude of benefits demonstrated in randomized
controlled trials (RCTs), FOBT programmes should be based on the best available evidence.
This paper focuses on seven key characteristics we believe are most salient for a population
cancer-screening programme and explores the policy trade-offs in these characteristics that
result from inadequate funding. Trade-offs are defined as compromises made in one area to
obtain benefits in another.
METHODOLOGY
Comparative case study methodology was used to explore in detail the different versions of
FOBT screening programmes. This approach emphasizes the importance of describing and
interpreting events and their context, in order to illuminate more general issues.11 For us, the
wider issue was the relationship between evidence-informed policy decisions and the
implementation of these policy decisions in practice.
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Document collection—Major documents relating to the five programmes were
examined, beginning with background documents to the establishment of the UK and
Australian Pilot Programmes. The aim was to establish as complete a set of programme
documents as possible. Other sources included commissioned reports, guidelines, press
releases, election campaign documents, websites and federal government budget papers.
Interview respondents were also helpful in identifying additional relevant documents and
some provided copies of background correspondence.
Interviews—A total of 42 key respondents were interviewed between August 2007 and
October 2009 (34 from Australia and 8 from the UK). Interviews were semi-structured and
lasted between 30 and 90 minutes. Questions varied according to the participant’s role in
bowel cancer screening policy. All interviews were digitally recorded and transcribed by a
professional transcription service.
The Australian interviews were conducted first and purposive sampling was used to achieve
a maximum diversity sample, across clinical, methodological and policy expertise and
involvement across the policy development timeline. Members of the two major government
review committees4,6 were initially interviewed and our sample was extended based on
further document analysis and suggestions from respondents. Interviewees included
representatives from cancer organizations, academics, clinicians, former and current state
and federal bureaucrats and political advisors.
The UK interviewees were also selected using purposive sampling, with interviews
conducted in England and Scotland over a two-week period. Interviewees included those
involved in establishing and analysing the Pilots, as well as those responsible for running the
English and Scottish programmes. It was a small but highly knowledgeable group.
Email correspondence—Email correspondence was used to obtain information on the
Welsh and Northern Irish programmes, updates on the implementation of the English and
Scottish programmes, and information on the implementation within the six Australian
states and two territories. This added an additional six UK and eight Australian respondents
to the 42 key respondents interviewed via telephone or face-to-face, making a total of 56
informants. For confidentiality reasons, respondents are referred to only by their
identification number, preceded by UK (United Kingdom) or an A (Australia) given in
square brackets after quotations or references attributable to them.
Data analysis—Information obtained from the documents, interviews and email
correspondence was used to compile a table of the seven most salient programme
characteristics, as determined by discussion among the authors. Based on our reading of the
literature and interview responses from key informants, we proposed a set of ‘optimal’
features for each characteristic. We then compared what had actually happened in practice in
each of the five countries (Table 1) with these optimal features (Table 2). Interview data
provided insights into the rationale behind some programme implementation choices.
RESULTS
Our main findings are presented in Tables 1 and 2, followed by commentary on the types of
trade-offs involved for each of the seven characteristics. Details of programme
implementation within Australia are provided in Appendix A.
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Australia is the only country to not offer screening every two years, despite biennial
screening being part of the Australian Pilot programme’s suggested framework6 and the
Australian National Health and Medical Research Council (NHMRC) guidelines
recommending at least biennial FOBT screening.26 Although screening less often reduces
the cost of the programme, it is unlikely to improve its cost-effectiveness, as the expected
benefits of the programme are also reduced. The trade-off here is between the up-front costs
versus the longer-term cost-effectiveness of the programme. It is unlikely that the mortality
reductions attained in the RCTs are achievable in the Australian programme which only
offers screening to individuals at 50, 55 and 65.
2) Population coverage
The more people included in the target population, the greater the cost of a screening
programme. England’s total target population is five times larger than Scotland’s and
eighteen times larger than Australia’s. Bowel cancer screening is the first organized
screening programme offered to men and women, so the target population is much higher
than for programmes offered only to women in a similar age range. For example, in Scotland
the target population for breast cancer screening (women aged 50–70) is 672,200, compared
with that for bowel cancer screening (men and women aged 50–74) which is 1,471,800.27
Scotland’s choice to offer screening to 50–74 year olds was based on the Council of the
European Union’s recommendation,16 but suited Scotland’s desire for age-based equity: “I
think the whole ethos of the Scots Calvinistic sort of, Presbyterian approach is very socialist
… and everyone has to have equitable access to health services and there shouldn’t be
different tiers of delivery of health services” [UK03]. Because 74 year olds today are
healthier and have a longer life expectancy than when the trials were conducted in the late
1970s to early 1990s, demand may increase in the future. As one respondent noted “we’re
now beginning to find people over the age of 74 knocking on the door and saying what
about us?” [UK04].
The decision to initially limit screening to 60–69 year olds in England, Scotland and
Northern Ireland was pragmatic, reflecting the shortage of colonoscopy capacity in some
areas [UK05, UK11, UK13], but was in line with the then recommendations of the UK NSC
to routinely screen those in their 60s while allowing older people to request screening. The
lack of screening for those in their 50s was not an ideal arrangement, as the risk of bowel
cancer incidence and mortality does increase steadily from age 5028 –29 and trial evidence
included participants in this age range.8 Following approval by the UK NSC in April
2011,30 National Health Service (NHS) England has announced plans for once-only flexible
sigmoidoscopy screening at age 55, in addition to FOBT screening.31
Given the limited resources however, the decision to focus FOBT screening on the above
60s, where the majority of cancerous and pre-cancerous lesions will be found, makes sense.
In Australia, the decision to limit screening to 55 and 65 year olds (later expanded to include
50 year olds) was justified on the basis of the need to manage the capacity of health
services,32 although Australia has a much higher colonoscopy capacity per capita than the
UK.33 As a result, many of the people who may benefit most from screening, particularly
those aged 66–75 are not screened at all in the current Australian programme.
3) Quality of test
The choice of an FOBT represents a trade-off between the more costly but more accurate
immunochemical test (iFOBT), versus the less expensive but less accurate guaiac test
(gFOBT). Only Australia uses a quantitative automated iFOBT in their programme, which
has been found to have superior clinical benefits over gFOBTs used in the UK.18 –22
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The choice of test also affects the screening algorithm, which is a trade-off between
accuracy and convenience of testing for the screening participant. The iFOBT gives an
actionable result (test is positive or negative) and avoids the need for repeated retesting. In
England, participants may be required to complete a gFOBT up to three times and the
programme loses many participants to further testing due to the extended screening episodes
[UK03]. The programmes in Wales and Northern Ireland have adopted the Scottish
algorithm, which involves using gFOBT as the first test, and then following up people who
have a ‘weakly positive’ test (that is, 1–4 of 6 windows positive) with a qualitative iFOBT.
This ‘two tier’ approach is not without its problems. Although this strategy may reduce the
number of colonoscopies (by reducing the number of false positive tests), the overall
programme sensitivity is still limited by the sensitivity of the initial gFOBT.34
Ideally, a screening programme should be capable of finding all the pathology that exists in
the target population. In practice, this is usually not feasible. As van Rossum et al. have
noted: “Policy makers will determine the optimal cutoff value [the point at which the test is
considered to be positive or negative] on the basis of a largely arbitrary balance between the
acceptability of missing cancer and the possibility and acceptability of assigning essential
resources”.35 Scotland is currently conducting a trial of a quantitative automated iFOBT to
replace the current algorithm, but even if funded, the positivity rate will still need to be set at
around 2% as their health system will not cope with additional colonoscopies required to
deal with a larger pathology yield [UK04].
4) Programme model
The English, Welsh and Northern Irish programmes follow a single funder exclusive
designated provider model. It separates the provision of screening colonoscopies from
symptomatic or surveillance colonoscopies, and so follows the model for breast cancer
screening. The developers of the UK breast cancer screening programme deliberately
differentiated between screening and non-screening cases, arguing that this was preferable,
because even though initially the women being screened for breast cancer may have better
facilities, it was important to first establish those high standards [UK07].
Scotland intentionally took a different approach because they did not want to create a ‘two-
tier’ system where people receiving colonoscopy as part of the screening programme were
guaranteed high quality colonoscopy, but those with symptoms or on a surveillance
programme were not [UK03]. Each of the fourteen Scottish health boards are responsibile
for ensuring a positive FOBT is treated in the same way as an urgent GP referral with fast-
tracked investigation and treatment [UK03]. In all four UK countries, most screening
follow-up is delivered in the public sector, without GP involvement.
In Australia, the bowel cancer screening programme was established as a ‘usual care’ model,
with the federal government funding the screening pathway only up to the point of a positive
FOBT. The state and territory governments, which are responsible for funding of hospital-
based services, were left to cover the costs of colonoscopy facilities for follow-up of positive
FOBTs performed in the public sector.
5) Quality of follow-up of positive test
In the designated provider jurisdictions in the UK, a central body is responsible for
organising pre-colonoscopy assessment appointments by specialized staff for those with
positive FOBTs. In Scotland pre-colonoscopy assessment is arranged by local NHS boards
and the quality may vary [UK04]. Similarly, in Australia there is no nationally coordinated
process for pre-colonoscopy assessment, which is organized through GPs who may lack
screening expertise or the time to devote to discussion of the pros and cons of further testing.
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There is the potential for screening colonoscopies to impact on waiting times for people
needing surveillance colonoscopies or those presenting with symptoms. Countries with
limited colonoscopy capacity may find this difficult to manage. In Australia, over 500,000
colonoscopies are performed annually. As at January 2010, less than 29,000 colonoscopies
were undertaken through the National Bowel Cancer Screening Program (NBCSP),36 so
colonoscopy capacity is not the major issue. The choice of the ‘usual care’ model, however,
has led to wide variation in the quality of follow-up between the States (see Appendix A).
Over 75% of colonoscopies performed in Australia are carried out in the private sector.33
Although this reduces the financial impact of a screening programme on public sector
facilities, the federal government still pays the majority of colonoscopy costs through the fee
for service-based Medicare Benefits Schedule. Participants are reimbursed through their
private health insurance (if covered) but are liable for any ‘gap’ payment if there is a
difference between the private health fund reimbursement and the private colonoscopist’s
fee (which is very likely). Reliance on the private sector may discriminate against those
without private health insurance (55% of all Australians)37 as colonoscopy waiting times are
often longer in the public sector [A38, A39].
6) Quality of colonoscopy
The quality of the colonoscopy itself is determined by the training and experience of the
colonoscopist and the standard of facilities (personnel and equipment) available. England
has established high standards in certification and accreditation procedures, and the other
UK countries have largely followed its lead. A recent report from the Australian NBSCP
Quality Working Group has recommended the introduction of a national scheme for
certification and re-certification of competence in colonoscopy –based on many features of
the English model33 – but applying to all colonoscopy, not just screening. The ‘usual care’
model adopted in Scotland and most of Australia, can lead to difficulties in assessing the
quality of screening colonoscopy, which may vary across regions [UK04].33
7) Quality of data collection
The quality of data collection is closely related to the programme model. England, Wales
and Northern Ireland, where clinical outcomes data is linked to a central register, are much
better positioned than Scotland and Australia which rely on this information being
forwarded to a central register. In Scotland, the NHS health boards collect clinical data on
different IT systems and are responsible for feeding that data back to the central Information
Services Division (ISD) within NHS Scotland. Although the health boards are required to
deliver the data, they do always provide all the necessary data in the appropriate form
[UK04].
In Australia, the situation is even less coordinated. The programmes in all states except
Queensland rely on individual clinicians – GPs, colonoscopists and histopathologists –to
return data to the central programme register run by Medicare Australia, and the rates of
return, particularly by histopathologists, have been poor.36 England, despite having an
efficient data collection system in place, and a programme underway since mid-2006, has
not yet published any programme outcomes, although they are expected to be produced
annually in the near future [UK05]. The lack of reliable clinical outcomes data from all
countries except Scotland has made meaningful comparison of the relative performance of
each programme impossible.
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None of the programmes incorporated all of our proposed optimal features, with different
programmes using different combinations of them. Insufficient funding has forced
programme administrators to compromise on ideal implementation characteristics. England,
with a much larger population, has opted for a less expensive, less accurate test, while
Australia uses a more expensive, more accurate test, but only offers testing to three select
age groups: 50, 55 and 65. It is clear that a trade-off between accuracy of test (and cost) and
population coverage has been considered necessary in both settings. In contrast, Scotland is
the only country to offer screening to the ideal age range of 50–74, as it has prioritized a
philosophical commitment to age-based equity [UK03] over offering a more accurate (and
expensive) test to a more restricted age range. These kind of trade-offs are necessary in all
five countries because governments have baulked at the upfront costs of offering an optimal
bowel cancer screening programme.
For example, the Australian government has made a continuing commitment to fund
biennial breast and cervical cancer screening programmes for all women in the
recommended age ranges (50–69 for breast cancer; 18–69 for cervical cancer). Bowel cancer
kills more people each year than each of these cancers combined, and FOBT screening has
consistently been reported to be highly cost-effective.5– 6,24,38 Yet the Australian
Government appears to be weighting short-term costs more heavily than the potential future
cost savings and improved health outcomes.
Limitations of this study include the fact that the seven most salient programme
characteristics and some of our proposed optimal features are based on our detailed
examination of the different programmes and our considered opinion about what appears to
work best. This has been necessary because of the paucity of clinical outcomes data
available to support all of our assertions.
Further research could explore the potential efficiency gains of having one central funding
source for all cancer screening, and redistributing funding according to relative cost-
effectiveness.
CONCLUSION
This review raises the broader question of the role of evidence in policy and practice, by
demonstrating the clear link between funding and evidence-based practice. All five bowel
cancer screening programmes are being delivered in different, but potentially inefficient,
ways. The irony is that by delivering programmes that do not optimize operational
efficiency, governments may not be achieving the net health benefits of FOBT screening
that justified the initial decision to fund them in the first place.
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Table 2
Trade-offs involved in FOBT cancer screening programmes with inadequate funding
Characteristic Features More funding/resources Less funding/resources Optimal features
Frequency N/A More often Less often At least biennial8
Population coverage Invited age range More people in the
appropriate age range
Less people in the
appropriate age range
50 to 74 or 75 year
olds16–17
Participation rates Maximize for all people,
including population sub-
groupsa to ensure equity of
access
Aim for 60% but may be
a one-size fits all
programme










Quality of test Type of test Most accurate Most affordable Quantitative
immunochemical
FOBT18– 22




Positive predictive value Higher Lower The combined PPVs
for cancer and
advanced adenomas




Screening algorithm Minimizes re-testing and
inconvenience
May involve up to three
FOBTs
FOBT with actionable
result after one test
(positive or negative),
and no dietary or
medication
restrictionsd
Programme model Invitation register Able to exclude in advance
those not suitable for
FOBT screening
General invitation to all




Funding Single funder Multiple funders Single funder to
provide adequate





Provider Designated provider Usual cared Designated providers
to set minimum
quality standards and
mandate return of data
to registerd,e
Quality of follow-up of
positive test
Who by? Staff with bowel cancer
screening knowledge and
expertise







up and ensure safety













Flitcroft et al. Page 14
Characteristic Features More funding/resources Less funding/resources Optimal features
by assessing pre-
colonoscopy riskd
Waiting times Shorter Longer Within 28 days from
positive test to
colonoscopyf
























Return of data Specific IT systems
created for the bowel
cancer screening
programmes
Usual IT systems Specialized IT
systems to maximize
quantity and quality of
data returned to
registerd
Reporting of data Regular internal and
external reporting









Irrespective of age, ethnicity, income or geographical location.
b
The idea of setting participation ‘targets’ is contentious as it may lead to people being encouraged to be screened, rather than them making their
own genuinely informed choice about whether to be screened or not. Nevertheless, participation rates are used as a de facto measure of a screening
program’s success. A participation rate close to 60% was achieved in the Nottingham RCT23 and this has become an unofficial ‘acceptable’ or
target rate. The NHS Quality Improvement Scotland (QIS) standard for bowel screening uptake is 60%.13 This figure was also used by English
researchers to model potential population-based bowel cancer screening programmes24 and representatives from all four UK screening
programmes were keen to establish participation rates at around this level or higher [UK02, UK05, UK11, UK13], although there is evidence that
high participation in bowel cancer screening programmes is not necessary to achieve cost-effectiveness.25 In Australia, where there is a large
amount of opportunistic bowel cancer screening outside the programme (mainly via colonoscopy but also through some independent FOBT
programmes such as the one run by Rotary) a participation rate of 60% may be more unrealistic.
c
Participation in both the UK5 and Australian6 pilots varied according to population sub-groups, and this was identified as an issue that needed to
be addressed.
d
In our considered opinion. These ideal features are based on what seems to work best and/or appears to have the best clinical outcomes, in the
absence of definitive evidence.
e
The usual care model, while less expensive than a designated provider model, may also be chosen on equity, rather than cost grounds. It ensures
all people requiring colonoscopy, whether screen-detected or not, have access to the same standard of care.
f
This is the ideal maximum waiting time specified in the English, Welsh and Northern Irish programmes. It is not achieved in all areas of these
countries.
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